Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 02:02PM ET
3.88
Dollar change
+0.23
Percentage change
6.30
%
IndexRUT P/E- EPS (ttm)-2.13 Insider Own57.86% Shs Outstand97.38M Perf Week12.46%
Market Cap465.72M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float50.58M Perf Month5.43%
Income-217.44M PEG- EPS next Q-0.38 Inst Own36.62% Short Float32.77% Perf Quarter-30.09%
Sales0.59M P/S789.35 EPS this Y24.72% Inst Trans4.87% Short Ratio12.85 Perf Half Y-37.22%
Book/sh1.64 P/B2.37 EPS next Y13.67% ROA-80.45% Short Interest16.57M Perf Year-56.31%
Cash/sh1.36 P/C2.86 EPS next 5Y- ROE-99.58% 52W Range3.28 - 9.86 Perf YTD-56.21%
Dividend Est.- P/FCF- EPS past 5Y-193.88% ROI-93.34% 52W High-60.65% Beta2.14
Dividend TTM- Quick Ratio8.23 Sales past 5Y-25.00% Gross Margin-1333.50% 52W Low18.29% ATR (14)0.35
Dividend Ex-DateSep 10, 2019 Current Ratio8.23 EPS Y/Y TTM-25.50% Oper. Margin-35535.53% RSI (14)51.58 Volatility8.86% 8.95%
Employees234 Debt/Eq0.21 Sales Y/Y TTM- Profit Margin-36791.71% Recom1.33 Target Price13.45
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q0.92% Payout- Rel Volume1.98 Prev Close3.65
Sales Surprise-100.00% EPS Surprise-18.01% Sales Q/Q- EarningsAug 08 BMO Avg Volume1.29M Price3.88
SMA204.27% SMA50-5.32% SMA200-36.25% Trades Volume1,819,990 Change6.30%
Date Action Analyst Rating Change Price Target Change
May-20-24Initiated H.C. Wainwright Buy $10
May-16-24Upgrade Citigroup Neutral → Buy $10
Apr-22-24Initiated Chardan Capital Markets Buy $17
Apr-08-24Initiated TD Cowen Buy
Apr-03-24Initiated Wedbush Outperform $12
Jan-16-24Downgrade Stifel Buy → Hold $18 → $9
Dec-08-23Initiated Citigroup Neutral $10
Oct-09-23Initiated BMO Capital Markets Outperform $19
Jul-31-23Initiated Guggenheim Buy $24
Apr-18-23Initiated Stifel Buy $18
Oct-01-24 09:33AM
Sep-30-24 06:08PM
08:38AM
07:01AM
07:00AM
06:30AM Loading…
06:30AM
Aug-28-24 08:15AM
08:00AM
Aug-08-24 08:00AM
Jul-31-24 01:53PM
Jul-19-24 10:00AM
Jul-08-24 05:44PM
12:30PM
May-30-24 09:55AM
08:00AM
06:30AM Loading…
May-29-24 06:30AM
May-25-24 04:10AM
May-20-24 09:32PM
09:33AM
May-17-24 06:27AM
06:15AM
May-16-24 07:14AM
May-14-24 09:55AM
May-13-24 11:12AM
08:00AM
May-12-24 03:00AM
May-10-24 02:23PM
01:53PM
08:00AM
May-08-24 08:00AM
12:00PM Loading…
May-03-24 12:00PM
May-01-24 08:00AM
Apr-30-24 06:01AM
Apr-29-24 10:12AM
07:35AM
07:33AM
07:00AM
Apr-23-24 08:00AM
Mar-27-24 08:45AM
Mar-14-24 02:44PM
Mar-01-24 02:00PM
08:00AM
Feb-29-24 03:02AM
Feb-28-24 08:00AM
Feb-20-24 04:01PM
Feb-14-24 11:50PM
04:05PM
Feb-01-24 08:00AM
Jan-25-24 08:00AM
Jan-09-24 06:21PM
Jan-05-24 05:00PM
08:00AM
Jan-02-24 08:00AM
Dec-19-23 10:30AM
Nov-30-23 07:45AM
Nov-08-23 08:00AM
Nov-03-23 04:01PM
Oct-30-23 03:46PM
Oct-27-23 06:00AM
Oct-24-23 07:30AM
05:04AM
Oct-23-23 02:50AM
Oct-17-23 08:00AM
Oct-09-23 09:33AM
Sep-19-23 08:00AM
Aug-31-23 08:00AM
Aug-07-23 04:01PM
Jul-25-23 07:45AM
Jun-29-23 08:46AM
Jun-22-23 08:00AM
Jun-02-23 10:15AM
May-31-23 08:00AM
May-26-23 09:45AM
May-17-23 04:05PM
06:00AM
May-11-23 08:00AM
Mar-27-23 08:00AM
Mar-09-23 08:00AM
Feb-27-23 08:00AM
Jan-20-23 05:56AM
Jan-09-23 07:00AM
Jan-03-23 08:00AM
Nov-01-22 04:13PM
Oct-24-22 05:30PM
Oct-20-22 12:45PM
Oct-19-22 09:47PM
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NELSEN ROBERTDirectorFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:41 PM
ARCH Venture Partners XII, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:38 PM
ARCH Venture Partners X, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:37 PM